Ligand Pharmaceuticals Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual report, not a standalone fourth-quarter report. Following the November 1, 2022 OmniAb spin-off, OmniAb is reported as discontinued operations; continuing-operation comparisons were retrospectively adjusted.
Business context
Ligand earns revenue primarily from royalties on partnered products, Captisol material sales, and contract revenue from licenses, milestones, and services. Its portfolio also includes Pelican Expression Technology and development-stage assets. After separating OmniAb, Ligand describes itself as a biopharmaceutical company focused on developing or acquiring technologies and assets used by pharmaceutical partners.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 | Change or context |
|---|---|---|---|
| Revenue | $196.2 million | $241.5 million | Down 19% |
| Royalties | $72.5 million | $48.9 million | Up 48% |
| Captisol revenue | $104.5 million | $164.3 million | COVID-related sales fell to $88.1 million from $140.8 million; core sales fell to $16.4 million from $23.4 million |
| Contract revenue | $19.2 million | $28.4 million | Down 32%, primarily due to milestone timing |
| Operating income | $3.0 million | $103.9 million | Operating costs rose to $193.2 million from $137.7 million |
| Net income (loss) from continuing operations | $(5.2) million | $76.4 million | 2022 included $41.2 million income tax expense |
| Consolidated net income (loss) | $(33.4) million | $57.1 million | Includes discontinued-operations losses of $28.1 million and $19.2 million, respectively |
| Cash provided by operating activities | $137.9 million | $78.8 million | 2022 cash generation included collections on receivables |
| Cash, cash equivalents and short-term investments | $211.9 million | — | Down $129.2 million year over year |
| 2023 convertible notes | $76.9 million principal outstanding | $343.3 million | Ligand repurchased $266.4 million principal for $261.4 million cash in 2022 |
Reported operating income equated to an approximately 1.5% operating margin (calculated from reported figures). The balance sheet showed $263.6 million of current assets and $98.8 million of current liabilities. Short-term investments included $63.1 million of Viking Therapeutics stock. Ligand said existing funds, operating cash flow, and financing access were adequate for working capital, debt service, R&D, and planned strategic initiatives.
Material changes, outlook, and risks
- Revenue mix shifted: Royalty growth—led by teriparatide, Rylaze, and Kyprolis—partly offset lower Captisol sales tied to reduced remdesivir demand. Royalties from products using the Pelican platform contributed over one-third of total royalty revenue; Captisol-enabled products contributed over half of royalty revenue.
- OmniAb separation: Ligand distributed its OmniAb business to shareholders and no longer consolidates it after the transaction. OmniAb’s FY 2022 discontinued-operations net loss was $28.1 million. The separation also involved management and board changes; Todd Davis became CEO in December 2022.
- Unusual expense and tax items: Ligand recorded a $9.8 million impairment of a Captisol capacity-ramp-up right-of-use asset as COVID-related demand forecasts declined. General and administrative expense rose 50% to $70.1 million, including higher stock compensation and a one-time former-CEO retirement charge. A $24.8 million valuation allowance adjustment was a major contributor to the 2022 tax expense and reported continuing-operations loss.
- Investment gains: Other income included a $28.5 million gain from short-term investments, primarily reflecting an unrealized $32.2 million gain on Viking stock. This investment is market-sensitive and may affect reported earnings.
- Partner pipeline: Management highlighted partner-reported milestones expected in 2023, including potential regulatory decisions or filings for sparsentan, ensifentrine, berdazimer gel, pradefovir, and other programs. These are partner expectations, not Ligand guidance or guaranteed outcomes.
- Key risks: Revenue depends on partners’ product sales, development decisions, and milestone timing; two partners each generated at least 10% of revenue (45% and 16%). Captisol supply depends primarily on Hovione, and the supply agreement carried $28.7 million of purchase obligations at year-end. Generic competition, clinical or regulatory setbacks, reimbursement and pricing changes, intellectual-property disputes, and market volatility could adversely affect results. The filing notes generic Evomela entry is permitted in the U.S. in 2026 or earlier under certain conditions, and a reported Kyprolis generic launch could occur in 2027 or sooner.
Ligand did not provide company-wide forward revenue or earnings guidance in the supplied filing text. Its outlook discussion emphasizes partner-driven development and commercialization, potential acquisitions, and the uncertainty of milestone and royalty revenue.
Investor facts to verify
- How much of future revenue and cash generation depends on the largest partners and on Captisol demand, particularly remdesivir-related sales?
- What is the status and repayment or conversion outcome of the remaining $76.9 million of 2023 notes, given their stated maturity year?
- Are partner pipeline timelines and approvals progressing as expected, and what royalties or milestones would actually accrue to Ligand?
- How sensitive are results to Viking’s share price, tax valuation allowances, and potential further asset impairments?
- Can Ligand maintain Captisol supply and manage its $28.7 million Hovione purchase commitment as demand changes?
The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting as of December 31, 2022.